Lantern Pharma(纳斯达克股票代码:LTRN)宣布,将Open-Medicine AI独立分拆,以加快其多智能体AI协同科学家平台的商业化进程,并拓展其应用边界,旨在彻底改造医学领域。这一战略举措,旨在将该前沿技术平台推向更广阔的市场,释放其潜在价值。
Lantern Pharma(纳斯达克股票代码:LTRN)宣布,将Open-Medicine AI独立分拆,以加快其多智能体AI协同科学家平台的商业化进程,并拓展其应用边界,旨在彻底改造医学领域。这一战略举措,旨在将该前沿技术平台推向更广阔的市场,释放其潜在价值。
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.